Immunotherapy Pioneered at MSK Receives FDA Approval for Advanced Kidney Cancer
Reporter: Aviva Lev-Ari, PhD, RN
Thanks to the work of MSK’s Robert Motzer, people with advanced renal cell carcinoma (a type of kidney cancer) now have a new immunotherapy option available to them.
Sourced through Scoop.it from: www.mskcc.org
Leave a Reply